Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04375761 · ClinicalTrials.gov registry record
COVID-19: Human Epidemiology and Response to SARS-CoV-2
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 5,599
- Enrollment target
NCT04375761: Completed study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT04375761 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 5,599 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04375761 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 5,599 participants
- Enrollment target
Study Summary
The human disease caused by SARS-CoV-2 is called COVID-19. In most cases, COVID-19 presents as a mild to moderate respiratory illness. But it can also be more severe and even lead to death. The purpose of this study is to: * Determine the prevalence of SARS-CoV-2 carrier status over time in children and parents * Determine the prevalence of antibody development over time in children and parents * Compare carrier status and antibody development for children with asthma and/or other atopic conditions (e.g. eczema) versus children without asthma and/or other atopic conditions * Investigate the presence of SARS-CoV-2 exposure in historical samples from enrolled participants
Primary Outcome
Nasal samples were analyzed to determine whether a participant ever tested positive for SARS-CoV-2 or not over the course of the study. Kaplan-Meier was used to estimate survival probabilities at timepoints throughout the study. Participants were censored if they did not test positive for SARS-CoV-2 by the end of follow-up. The last positive nasal swab occurred at day 212.
Interventions
- PROCEDURE Collection of Biological Samples
- PROCEDURE Symptom and Exposure Surveys
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,599 participants |
| Start Date | 2020-05-01 |
| Est. Completion | 2021-03-29 |
What the finished NCT04375761 record still lists
NCT04375761 is an observational study that tracks outcomes without assigning an intervention. Its 5,599 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Collection of Biological Samples is the first listed.
NCT04375761 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04375761 about?
NCT04375761 is a clinical study titled "COVID-19: Human Epidemiology and Response to SARS-CoV-2". The human disease caused by SARS-CoV-2 is called COVID-19. In most cases, COVID-19 presents as a mild to moderate respiratory illness. But it can also be more severe and even lead to death. The purpose of this study is to: * Determine the prevalence of SARS-CoV-2 carrier status over time in childr...
What is the current status of trial NCT04375761?
This trial is currently completed. The enrollment target is 5,599 participants. The study started on 2020-05-01. Estimated completion is 2021-03-29.
What interventions are being tested in trial NCT04375761?
The interventions under investigation include: Collection of Biological Samples (PROCEDURE), Symptom and Exposure Surveys (PROCEDURE).
Who is sponsoring clinical trial NCT04375761?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05636176 · 5,600 participants · Phase 3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
- NCT06981598 · 5,586 participants · NA
Prevention of Psychological Health Problems Via Integrated Operational Support
- NCT06627335 · 5,621 participants
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
- NCT07146568 · 5,515 participants · NA
Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hospital
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI